Sunita D. Nasta, MD, FACP

faculty photo
Associate Professor of Clinical Medicine
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-159
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-662-3933
Fax: 215-615-5887
BS (Microbiology & Immunology)
Stanford University, Palo Alto, CA , 1991.
Medical College of Virginia, Richmond, VA, 1995.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

Clinical trials in non-Hodgkin's lymphoma, phase I, II and III

Description of Clinical Expertise

1.Management of patients with Non-Hodgkin's lymphoma, Hodgkin's Lymphoma, multiple myeloma, acute and chronic leukemias with standard therapy as well as clinical experimental therapies using new agents.
2. Bone Marrow and Stem Cell Transplantation, autologous and allogeneic.
3. Special interest in treating patients with aggressive non-Hodgkin's lymphoma, lymphoma in the elderly and lymphoma in the pregnant patient.
4. Special interest in the long-term follow-up of patients with Hodgkin's lymphoma and survivors issues.

Selected Publications

Hivnor CM, Nguyen V, Rook AH, Junkins-Hopkins J, Gelfand JM, Nasta S, Frank I, Kim EM: CD8+ lymphoma in a patient with human immunodeficiency virus. Arch Dermatol 141(10): 1321-2, Oct 2005.

Tsai DE, Aqui NA, Vogl DT, Bloom RD, Schuster SJ, Nasta SD, Wasik MA : Successful treatment of T-cell post-transplant lymphoproliferative disorder with the retinoid analog bexarotene. Am J Transplant 5(8): 2070-3, Aug 2005.

Vogl DT, Glatstein E, Carver JR, Schuster SJ, Stadtmauer EA, Luger S, Nasta SD, Porter DL, Elstrom R, Tsai DE : Gemcitabine-induced pericardial effusion and tamponade after unblocked cardiac irradiation. Leuk Lymphoma. 46(9): 1313-20, Sep 2005.

Loren AW, Luger SM, Stadtmauer EA, Tsai DE, Schuster S, Nasta SD, Goldstein SC, Perl A, Orloff G, Oliver JC, Green J, Emerson SG, Porter DL: Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation. Bone Marrow Transplantation 35(9): 921-6, May 2005.

Tsai DE, Maillard I, Downs LH, Alavi A, Nasta SD, Glatstein E, Schuster SJ: Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia. Leuk Lymphoma. 45(3): 591-5, Mar 2004.

Nasta SD, Hoff PM, GeorgeCM, Neubauer, M, Cohen SC, Abbruzzese JA, Winn R., Pazdur RM : “Phase II Study of MGI-114 Administered Intravenously for Five Days Every 28 Days to Patients with Metastatic Colorectal Cancer” Am J Clin Oncol. 26(2): 132-4, Apr 2003.

Nasta SD, Carrum G., Shahab I., Hanania N, Udden MM: “Regression of a Plasmablastic Lymphoma in a Patient with HIV on Highly Active Antiretroviral Therapy” Leuk Lymphoma 43(2): 423-426, Feb 2002.

Cohen AD, Luger SM, Sickles C, Mangan PA, Porter DL, Schuster SJ, Tsai DE, Nasta S, Gewirtz AM, Stadtmauer EA: “ Gemtuzumab ozogamicin (Mylotarg) monotherapy for relapsed AML after hematopoietic stem cell transplant: efficacy and incidence of hepatic veno-occlusive disease" Bone Marrow Transplant 30(1): 23-28, July 2002.

Dwivedy, S: “Hodgkin’s Disease: Clinical Management and Future Perspectives” Fellows Reporter 6(3), April 2001.

Dwivedy S,. Hoff P. M, Dumas P.,. Lassere Y,. Aguayo A,. Hayakawa T, Abbruzzese J.L.: Safety and phamacokinetics (PK) of an antitumor/antiangiogenic agent, TAS-102: a phase I study for patients(pts) with solid tumors. ASCO 2001 Notes: Accepted.

back to top
Last updated: 03/02/2020
The Trustees of the University of Pennsylvania